메뉴 건너뛰기




Volumn 6, Issue 1, 2013, Pages 93-98

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen

Author keywords

Breast cancer; CYP3A4 5; Disease free survival; Drug transporters; Pharmacogenetics; Tamoxifen

Indexed keywords

ALANINE; CYSTEINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; TAMOXIFEN; THREONINE;

EID: 84883228374     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S44006     Document Type: Article
Times cited : (28)

References (42)
  • 1
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
    • (2005) Lancet. , vol.365 , Issue.9472 , pp. 1687-1717
  • 2
    • 4243063941 scopus 로고    scopus 로고
    • Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450system in vitro: Prominent roles for CYP3A and CYP2D6
    • Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062-1075.
    • (2004) J Pharmacol Exp Ther. , vol.310 , Issue.3 , pp. 1062-1075
    • Desta, Z.1    Ward, B.A.2    Soukhova, N.V.3    Flockhart, D.A.4
  • 3
    • 67749114265 scopus 로고    scopus 로고
    • CYP2D6 and tamoxifen: DNA matters in breast cancer
    • Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576-586.
    • (2009) Nat Rev Cancer. , vol.9 , Issue.8 , pp. 576-586
    • Hoskins, J.M.1    Carey, L.A.2    McLeod, H.L.3
  • 4
    • 80455168584 scopus 로고    scopus 로고
    • Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P1 and P2 clinical trials
    • Goetz MP, Schaid DJ, Wickerham DL, etal. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res. 2011;17(21):6944-6951.
    • (2011) Clin Cancer Res. , vol.17 , Issue.21 , pp. 6944-6951
    • Goetz, M.P.1    Schaid, D.J.2    Wickerham, D.L.3
  • 5
    • 84859054082 scopus 로고    scopus 로고
    • CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
    • ATAC trialists
    • Rae JM, Drury S, Hayes DF, etal; ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.
    • (2012) J Natl Cancer Inst. , vol.104 , Issue.6 , pp. 452-460
    • Rae, J.M.1    Drury, S.2    Hayes, D.F.3
  • 6
    • 84859093970 scopus 로고    scopus 로고
    • CYP2D6genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial
    • Breast International Group (BIG) 1-98 Collaborative Group
    • Regan MM, Leyland-Jones B, Bouzyk M, etal; Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441-451.
    • (2012) J Natl Cancer Inst. , vol.104 , Issue.6 , pp. 441-451
    • Regan, M.M.1    Leyland-Jones, B.2    Bouzyk, M.3
  • 7
    • 84875388654 scopus 로고    scopus 로고
    • Variants in tamoxifen metabolizing genes: A case-control study of contralateral breast cancer risk in the WECARE study
    • WECARE Study Collaborative Group
    • Brooks JD, Teraoka SN, Malone KE, etal; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC. Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. Int J Mol Epidemiol Genet. 2013;4(1):35-48.
    • (2013) Int J Mol Epidemiol Genet. , vol.4 , Issue.1 , pp. 35-48
    • Brooks, J.D.1    Teraoka, S.N.2    Malone, K.E.3    Bernstein, J.L.4    Figueiredo, J.C.5
  • 8
    • 0027221052 scopus 로고
    • Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation
    • Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos. 1993;21(4):645-656.
    • (1993) Drug Metab Dispos. , vol.21 , Issue.4 , pp. 645-656
    • Mani, C.1    Gelboin, H.V.2    Park, S.S.3    Pearce, R.4    Parkinson, A.5    Kupfer, D.6
  • 9
    • 79956196206 scopus 로고    scopus 로고
    • P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration
    • Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration. J Pharmacol Exp Ther. 2011;337(3):710-717.
    • (2011) J Pharmacol Exp Ther. , vol.337 , Issue.3 , pp. 710-717
    • Iusuf, D.1    Teunissen, S.F.2    Wagenaar, E.3    Rosing, H.4    Beijnen, J.H.5    Schinkel, A.H.6
  • 10
    • 34547781742 scopus 로고    scopus 로고
    • Induction of multidrug resistance associated protein 2in tamoxifen-resistant breast cancer cells
    • Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer. 2007;14(2):293-303.
    • (2007) Endocr Relat Cancer. , vol.14 , Issue.2 , pp. 293-303
    • Choi, H.K.1    Yang, J.W.2    Roh, S.H.3    Han, C.Y.4    Kang, K.W.5
  • 11
    • 0035197548 scopus 로고    scopus 로고
    • Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos
    • Dai D, Tang J, Rose R, etal. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299(3):825-831.
    • (2001) J Pharmacol Exp Ther. , vol.299 , Issue.3 , pp. 825-831
    • Dai, D.1    Tang, J.2    Rose, R.3
  • 12
    • 0035217180 scopus 로고    scopus 로고
    • The genetic determinants of the CYP3A5 polymorphism
    • Hustert E, Haberl M, Burk O, etal. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11(9): 773-779.
    • (2001) Pharmacogenetics. , vol.11 , Issue.9 , pp. 773-779
    • Hustert, E.1    Haberl, M.2    Burk, O.3
  • 13
    • 0041831261 scopus 로고    scopus 로고
    • Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
    • Hesselink DA, van Schaik RH, van der Heiden IP, etal. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74(3):245-254.
    • (2003) Clin Pharmacol Ther. , vol.74 , Issue.3 , pp. 245-254
    • Hesselink, D.A.1    van Schaik, R.H.2    van der Heiden, I.P.3
  • 14
    • 33847249931 scopus 로고    scopus 로고
    • Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex
    • Haenisch S, Zimmermann U, Dazert E, etal. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007;7(1):56-65.
    • (2007) Pharmacogenomics J. , vol.7 , Issue.1 , pp. 56-65
    • Haenisch, S.1    Zimmermann, U.2    Dazert, E.3
  • 15
    • 33846504706 scopus 로고    scopus 로고
    • A "silent" polymorphism in the MDR1gene changes substrate specificity
    • Kimchi-Sarfaty C, Oh JM, Kim IW, etal. A "silent" polymorphism in the MDR1gene changes substrate specificity. Science. 2007;315(5811): 525-528.
    • (2007) Science. , vol.315 , Issue.5811 , pp. 525-528
    • Kimchi-Sarfaty, C.1    Oh, J.M.2    Kim, I.W.3
  • 16
    • 34248547635 scopus 로고    scopus 로고
    • MRP2 haplotypes confer differential susceptibility to toxic liver injury
    • Choi JH, Ahn BM, Yi J, etal. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 2007;17(6):403-415.
    • (2007) Pharmacogenet Genomics. , vol.17 , Issue.6 , pp. 403-415
    • Choi, J.H.1    Ahn, B.M.2    Yi, J.3
  • 17
    • 78649320874 scopus 로고    scopus 로고
    • Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function
    • Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11(1):25-34.
    • (2011) Pharmacogenomics J. , vol.11 , Issue.1 , pp. 25-34
    • Laechelt, S.1    Turrini, E.2    Ruehmkorf, A.3    Siegmund, W.4    Cascorbi, I.5    Haenisch, S.6
  • 18
    • 77956242845 scopus 로고    scopus 로고
    • CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification
    • Schroth W, Hamann U, Fasching PA, etal. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res. 2010;16(17):4468-4477.
    • (2010) Clin Cancer Res. , vol.16 , Issue.17 , pp. 4468-4477
    • Schroth, W.1    Hamann, U.2    Fasching, P.A.3
  • 19
    • 79955485361 scopus 로고    scopus 로고
    • Tamoxifen metabolite concentrations, CYP2D6genotype, and breast cancer outcomes
    • Madlensky L, Natarajan L, Tchu S, etal. Tamoxifen metabolite concentrations, CYP2D6genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718-725.
    • (2011) Clin Pharmacol Ther. , vol.89 , Issue.5 , pp. 718-725
    • Madlensky, L.1    Natarajan, L.2    Tchu, S.3
  • 20
    • 47749105202 scopus 로고    scopus 로고
    • Association between CYP2D6 *10genotype and survival of breast cancer patients receiving tamoxifen treatment
    • Xu Y, Sun Y, Yao L, etal. Association between CYP2D6 *10genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19(8):1423-1429.
    • (2008) Ann Oncol. , vol.19 , Issue.8 , pp. 1423-1429
    • Xu, Y.1    Sun, Y.2    Yao, L.3
  • 21
    • 77950502100 scopus 로고    scopus 로고
    • Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients
    • Kiyotani K, Mushiroda T, Imamura CK, etal. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8): 1287-1293.
    • (2010) J Clin Oncol. , vol.28 , Issue.8 , pp. 1287-1293
    • Kiyotani, K.1    Mushiroda, T.2    Imamura, C.K.3
  • 22
    • 80052665548 scopus 로고    scopus 로고
    • Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment
    • Park HS, Choi JY, Lee MJ, etal. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci. 2011;26(8):1007-1013.
    • (2011) J Korean Med Sci. , vol.26 , Issue.8 , pp. 1007-1013
    • Park, H.S.1    Choi, J.Y.2    Lee, M.J.3
  • 23
    • 70349899258 scopus 로고    scopus 로고
    • No association between CYP2D6*10genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment
    • Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D6*10genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol. 2009;39(10):651-656.
    • (2009) Jpn J Clin Oncol. , vol.39 , Issue.10 , pp. 651-656
    • Toyama, T.1    Yamashita, H.2    Sugiura, H.3    Kondo, N.4    Iwase, H.5    Fujii, Y.6
  • 24
    • 84874017348 scopus 로고    scopus 로고
    • Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: A microarray-based study in Thailand
    • Sukasem C, Sirachainan E, Chamnanphon M, etal. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev. 2012;13(9):4549-4553.
    • (2012) Asian Pac J Cancer Prev. , vol.13 , Issue.9 , pp. 4549-4553
    • Sukasem, C.1    Sirachainan, E.2    Chamnanphon, M.3
  • 25
    • 84878302608 scopus 로고    scopus 로고
    • Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
    • Chamnanphon M, Pechatanan K, Sirachainan E, et al. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenomics Pers Med. 2013;6:37-48.
    • (2013) Pharmgenomics Pers Med. , vol.6 , pp. 37-48
    • Chamnanphon, M.1    Pechatanan, K.2    Sirachainan, E.3
  • 26
    • 61449171134 scopus 로고    scopus 로고
    • Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
    • Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115(5):952-961.
    • (2009) Cancer. , vol.115 , Issue.5 , pp. 952-961
    • Okishiro, M.1    Taguchi, T.2    Jin Kim, S.3    Shimazu, K.4    Tamaki, Y.5    Noguchi, S.6
  • 27
    • 36349024762 scopus 로고    scopus 로고
    • Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
    • Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.
    • (2007) J Clin Oncol. , vol.25 , Issue.33 , pp. 5187-5193
    • Schroth, W.1    Antoniadou, L.2    Fritz, P.3
  • 28
    • 79959684375 scopus 로고    scopus 로고
    • Analysis of CYP3A4 genetic polymorphisms in Han Chinese
    • Zhou Q, Yu X, Shu C, et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56(6):415-422.
    • (2011) J Hum Genet. , vol.56 , Issue.6 , pp. 415-422
    • Zhou, Q.1    Yu, X.2    Shu, C.3
  • 30
    • 79953848236 scopus 로고    scopus 로고
    • Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
    • Lim JSL, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71(5):737-750.
    • (2011) Br J Clin Pharmacol. , vol.71 , Issue.5 , pp. 737-750
    • Lim, J.S.L.1    Chen, X.A.2    Singh, O.3
  • 31
    • 19944434201 scopus 로고    scopus 로고
    • CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    • Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.
    • (2005) J Natl Cancer Inst. , vol.97 , Issue.1 , pp. 30-39
    • Jin, Y.1    Desta, Z.2    Stearns, V.3
  • 32
    • 79955480679 scopus 로고    scopus 로고
    • Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma
    • German Tamoxifen and AI Clinicians Group
    • Murdter TE, Schroth W, Bacchus-Gerybadze L, et al; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708-717.
    • (2011) Clin Pharmacol Ther. , vol.89 , Issue.5 , pp. 708-717
    • Murdter, T.E.1    Schroth, W.2    Bacchus-Gerybadze, L.3    Eichelbaum, M.4    Schwab, M.5    Brauch, H.6
  • 33
    • 33644639136 scopus 로고    scopus 로고
    • Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
    • Goetz M, Rae J, Suman V, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
    • (2005) J Clin Oncol. , vol.23 , Issue.36 , pp. 9312-9318
    • Goetz, M.1    Rae, J.2    Suman, V.3
  • 34
    • 10444221019 scopus 로고    scopus 로고
    • Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
    • Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005;217(1): 61-72.
    • (2005) Cancer Lett. , vol.217 , Issue.1 , pp. 61-72
    • Tucker, A.N.1    Tkaczuk, K.A.2    Lewis, L.M.3    Tomic, D.4    Lim, C.K.5    Flaws, J.A.6
  • 35
    • 77953679656 scopus 로고    scopus 로고
    • Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
    • Gjerde J, Geisler J, Lundgren S, etal. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 2010;10(1):313.
    • (2010) BMC Cancer. , vol.10 , Issue.1 , pp. 313
    • Gjerde, J.1    Geisler, J.2    Lundgren, S.3
  • 36
    • 84862930465 scopus 로고    scopus 로고
    • Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes
    • Mugundu GM, Sallans L, Guo Y, Shaughnessy EA, Desai PB. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. Drug Metab Dispos. 2012;40(2):389-396.
    • (2012) Drug Metab Dispos. , vol.40 , Issue.2 , pp. 389-396
    • Mugundu, G.M.1    Sallans, L.2    Guo, Y.3    Shaughnessy, E.A.4    Desai, P.B.5
  • 39
    • 84869839802 scopus 로고    scopus 로고
    • Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma
    • Baldissera VD, de Mattos AA, Coral GP, et al. Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol. 2012;11(6):899-906.
    • (2012) Ann Hepatol. , vol.11 , Issue.6 , pp. 899-906
    • Baldissera, V.D.1    de Mattos, A.A.2    Coral, G.P.3
  • 40
    • 0041627670 scopus 로고    scopus 로고
    • Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer
    • Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003;22(5):1117-1121.
    • (2003) Int J Oncol. , vol.22 , Issue.5 , pp. 1117-1121
    • Kafka, A.1    Sauer, G.2    Jaeger, C.3
  • 41
    • 60549112572 scopus 로고    scopus 로고
    • Association of the ABCB1 gene polymorphisms 2677G. T/A and 3435C. T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
    • Chang H, Rha SY, Jeung H-C, et al. Association of the ABCB1 gene polymorphisms 2677G. T/A and 3435C. T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009;20(2):272-277.
    • (2009) Ann Oncol. , vol.20 , Issue.2 , pp. 272-277
    • Chang, H.1    Rha, S.Y.2    Jeung, H.-C.3
  • 42
    • 0036731995 scopus 로고    scopus 로고
    • MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients
    • Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955-4962.
    • (2002) Cancer Res. , vol.62 , Issue.17 , pp. 4955-4962
    • Illmer, T.1    Schuler, U.S.2    Thiede, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.